Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-0814 in Exudative AMD
NCT03869684Phase 2Terminated
- Sponsor
- Senju Pharmaceutical Co., Ltd.
- Start
- Feb 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MT-0814 in exudative age-related macular degeneration, sponsored by Senju Pharmaceutical Co., Ltd.. Started Feb 2019; status: terminated.
02
Drugs
MT-0814
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT03869684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03869684.